InSphero, a Schlieren, Switzerland-based provider of 3D cell-based platforms for drug discovery and efficacy testing, raised $10m in funding.
The round brings total funding to date to USD$35m. Backers included former GM of Promega Switzerland Dr. Jürg Gysi, who is now President of the InSphero Board of Directors.
The company intends to use the funds to further enhance its discovery platforms for metabolic diseases and cancer.
Led by CEO and co-founder Dr. Jan Lichtenberg, InSphero provides comprehensive solutions for preclinical drug safety and efficacy testing based on 3D microtissues, which are phenotypic models of the smallest functional unit of a tissue or organ. These drug-discovery and testing platforms combine scalable 3D technology, ISO quality-controlled 3D human tissue models, 3D-optimized media, as well as tailored assay services and support.
The technology is used in ongoing research collaborations with academic and industry partners, such as Roche Pharmaceuticals in Basel, Switzerland, and the Swiss Federal Institute of Technology (ETH).